Hansa’s Q4 is slightly below our and the market’s sales expectations and slightly better in terms of OPEX and operating cash flow. Hansa has probably delivered Idefirix to seven patients vs our expected eight patients. Some transplant centers are expected to be ready for multiple-patient treatment in 2023. The trend of increasing partner sales contribution is also positive. We can expect 2023 with a gradual contribution from the early Idefirix launch and significant pipeline progress for several projects. We expect a neutral share price reaction based on Hansa’s Q4 result and the 2023 outlook.